Pemetrexed Injection, Powder, Lyophilized, For Solution
Product Images NDC 67184-0504

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Pemetrexed (NDC 67184-0504). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Qilu Pharmaceutical Co., Ltd., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Pemetrexed 01)

Chemical structure of Pemetrexed disodium, showing its molecular components including sodium ions and hydrate groups, as presented in the image.*

FDA Label Image

Figure 1 (Pemetrexed 02)

A Kaplan-Meier survival curve chart depicting overall survival (%) over time in months for two treatment arms involving Pemetrexed injection. The black line represents P+P+C (Pemetrexed, pembrolizumab, and platinum chemotherapy), and the gray line represents P+C (Pemetrexed, platinum chemotherapy, and placebo). The chart also shows the number of patients at risk over time for each arm.*

FDA Label Image

Figure 2 (Pemetrexed 03)

A Kaplan-Meier survival curve chart comparing survival probability over time in months for two treatment groups: Pemetrexed plus Cisplatin (PC) and Gemcitabine plus Cisplatin (GC). The chart includes a legend and a table below listing the number of patients at risk at various time points for each group.*

FDA Label Image

Figure 3 (Pemetrexed 04)

A Kaplan-Meier survival curve graph showing survival probability over time in months for two treatment groups: Pemetrexed combined with Cisplatin (PC) and Gemcitabine combined with Cisplatin (GC). The chart includes the number of patients at risk for each group at multiple time points up to 30 months.*

FDA Label Image

Figure 4 (Pemetrexed 05)

A Kaplan-Meier survival curve chart comparing survival probabilities over time in months for two treatment groups: Pemetrexed plus Cisplatin (solid line) and Gemcitabine plus Cisplatin (dotted line). It includes a table showing the number of patients at risk at various time points up to 30 months for both groups.*

FDA Label Image

Figure 5 (Pemetrexed 06)

A Kaplan-Meier survival curve comparing survival probability over time (in months) between patients treated with Pemetrexed and those given a placebo. The graph includes a table showing the number of patients at risk at various time points for both groups, illustrating survival trends up to about 39 months.*

FDA Label Image

Figure 6 (Pemetrexed 07)

A Kaplan-Meier survival curve graph comparing survival probability over time in months between patients treated with Pemetrexed and those given a placebo. The y-axis represents survival probability from 0 to 1, and the x-axis shows survival time up to 42 months. The solid line represents Pemetrexed, and the dotted line represents placebo, with patient counts at risk listed below the x-axis for each group.*

FDA Label Image

Figure 7 (Pemetrexed 08)

A survival probability curve chart comparing Pemetrexed injection versus placebo over survival time in months. The chart includes survival probability on the vertical axis and survival time from 0 to 42 months on the horizontal axis, with separate curves for Pemetrexed and placebo groups. The number of patients at risk is listed below the graph for both groups at various time points.*

FDA Label Image

Figure 8 (Pemetrexed 09)

A survival curve graph comparing survival probability over time in months between Pemetrexed and Placebo groups. The solid line represents Pemetrexed, and the dotted line represents Placebo, with both showing a decline in survival probability from 0 to 36 months. The graph includes a table of patients at risk at various time points for each group.*

FDA Label Image

Figure 9 (Pemetrexed 10)

A survival curve chart comparing survival probability over time in months between two treatment groups: Pemetrexed + Cisplatin (solid line) and Cisplatin alone (dotted line). Below the x-axis is a table showing the number of patients at risk at various time points for each group.*

FDA Label Image

Package Carton – Pemetrexed For Injection 100 mg Single-dose Vial (Pemetrexed 11)

Packaging label for Pemetrexed for Injection, USP 100 mg/vial by Qilu Pharmaceutical Co., Ltd. The label features a purple and white color scheme and includes text indicating the lyophilized powder for intravenous use. It states the strength as 100 mg per vial and provides storage instructions, manufacturer information, and a barcode. The label also highlights that the product is for intraveneous use only and prescription use only.*

FDA Label Image

Package Carton – Pemetrexed For Injection 500 mg Single-dose Vial (Pemetrexed 12)

Packaging label for Pemetrexed for Injection, USP 500 mg per vial. The label indicates the product is a single-dose vial containing pemetrexed disodium for intravenous use. It includes storage instructions, manufacturer details (Qilu Pharma, Inc. and Qilu Pharmaceutical (Hainan) Co., Ltd.), and a caution that it is a cytotoxic agent. The label also shows barcodes and dosage form as lyophilized powder for solution.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.